MedImmune, which makes the FluMist influenza vaccine, on Wednesday reaffirmed its financial guidance for the current year and beyond.

The biotechnology company expects to post a 2006 profit -- excluding stock option expenses -- of 17 cents to 22 cents per share on revenue of $1.3 billion. Analysts polled by Thomson Financial, who also exclude stock option expenses, forecast earnings of 19 cents per share on sales of $1.3 billion.

For 2007, MedImmune expects earnings per share of 90 cents to 95 cents on sales of $1.5 billion. Analysts expect a profit of 85 cents per share and sales of $1.45 billion.

The company also confirmed its 2009 financial targets of $2 billion in revenue and net income of $2.00 per share.